drugset / Trial / NCT01476280

Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting

NCT01476280

Completed 100 enrolled Incheon St.Mary's Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Ramosetron and palonosetron are more recently developed 5-hydroxytryptamine type 3 receptor antagonists and this randomized double blind study was designed to compare efficacy of ramosetron and palonosetron to prevent postoperative nausea and vomiting. Investigator hypothesized that palonosetron would have stronger and longer lasting antiemetic effect compared with ramosetron and evaluated the patients for the first 48 hours after surgery.

Timeline

Start
2011-05
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Palonosetron Other / unclassified 0.075 mg
Comparator Ramosetron Small molecule 0.3 mg

Indications

No indication recorded.